426 related articles for article (PubMed ID: 9887493)
1. [Late toxicity after chemotherapy of malignant testicular tumors].
Jakob A; Kollmannsberger C; Kanz L; Bokemeyer C
Urologe A; 1998 Nov; 37(6):635-47. PubMed ID: 9887493
[TBL] [Abstract][Full Text] [Related]
2. Treatment of testicular cancer and the development of secondary malignancies.
Bokemeyer C; Schmoll HJ
J Clin Oncol; 1995 Jan; 13(1):283-92. PubMed ID: 7799032
[TBL] [Abstract][Full Text] [Related]
3. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer.
Berger CC; Bokemeyer C; Schneider M; Kuczyk MA; Schmoll HJ
Eur J Cancer; 1995 Dec; 31A(13-14):2229-38. PubMed ID: 8652248
[TBL] [Abstract][Full Text] [Related]
4. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
5. Long-term complications of chemotherapy for germ cell tumours.
Chaudhary UB; Haldas JR
Drugs; 2003; 63(15):1565-77. PubMed ID: 12887263
[TBL] [Abstract][Full Text] [Related]
6. Late toxicity following curative treatment of testicular cancer.
Kollmannsberger C; Kuzcyk M; Mayer F; Hartmann JT; Kanz L; Bokemeyer C
Semin Surg Oncol; 1999 Dec; 17(4):275-81. PubMed ID: 10588857
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of long-term toxicity after chemotherapy for testicular cancer.
Bokemeyer C; Berger CC; Kuczyk MA; Schmoll HJ
J Clin Oncol; 1996 Nov; 14(11):2923-32. PubMed ID: 8918489
[TBL] [Abstract][Full Text] [Related]
8. Treatment of testicular cancer: a new and improved model.
Einhorn LH
J Clin Oncol; 1990 Nov; 8(11):1777-81. PubMed ID: 1700077
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
10. [Late damage of curative oncologic therapy. Results of a patient sample with Hodgkin's disease and testicular tumors at the Hannover Medical School].
Bokemeyer C
Med Klin (Munich); 1996 Apr; 91 Suppl 3():60-7. PubMed ID: 8692121
[TBL] [Abstract][Full Text] [Related]
11. Secondary neoplasms following treatment of malignant germ cell tumors.
Bokemeyer C; Schmoll HJ
J Clin Oncol; 1993 Sep; 11(9):1703-9. PubMed ID: 8394879
[TBL] [Abstract][Full Text] [Related]
12. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols.
Nichols CR; Breeden ES; Loehrer PJ; Williams SD; Einhorn LH
J Natl Cancer Inst; 1993 Jan; 85(1):36-40. PubMed ID: 7677934
[TBL] [Abstract][Full Text] [Related]
13. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
14. [Secondary leukemia following ultra high-dose chemotherapy with peripheral blood stem cell autotransplantation for refractory testicular cancer].
Matsumoto S; Matsuda H; Uejima S; Kurita T
Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):687-91. PubMed ID: 11109821
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.
Pont J; Albrecht W; Postner G; Sellner F; Angel K; Höltl W
J Clin Oncol; 1996 Feb; 14(2):441-8. PubMed ID: 8636755
[TBL] [Abstract][Full Text] [Related]
17. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of advanced testicular cancer.
Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
[TBL] [Abstract][Full Text] [Related]
19. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related malignancies following treatment of germ cell cancer.
Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
Int J Cancer; 1999 Dec; 83(6):860-3. PubMed ID: 10597212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
